CTKB: Amendment: SEC Form SCHEDULE 13G/A filed by Cytek Biosciences Inc.
Millennium and Integrated Core affiliates report 5.6% and 4.5% stakes in Cytek; passive holdings filing, no price catalyst.
What this filing says
Three entities tied to Millennium Management report stakes in Cytek Biosciences of 4.5% to 5.6% of the common stock, based on the filing's share counts. This is an amended Schedule 13G, a routine disclosure of a passive holder's position as of the stated event date, and it does not by itself indicate any change in control or management.
Key figures
- Integrated Core Strategies shares
- 5,870,954 shares
- Integrated Core Strategies stake
- 4.5%
- Millennium Management shares
- 7,281,488 shares
- Millennium Management stake
- 5.6%
- Event date
- 09/30/2026
Written by Quantisnow AI from this filing. Not financial advice.
Key terms
- Schedule 13G:
- A short-form filing used by passive investors who hold more than 5% of a company's shares and are not seeking to influence management.
- Beneficial ownership:
- Shares a person controls directly or through voting or investment power, even if held in another name.
- Shared voting power:
- The ability to vote shares together with another party rather than alone.
FAQ
What does this Cytek Biosciences 13G/A filing report?
It reports the current stakes held by Integrated Core Strategies, Millennium Management and related entities in Cytek Biosciences common stock, as of the 09/30/2026 event date.
Does the filing say the holders intend to influence Cytek Biosciences?
The filing does not state any intent to influence or control Cytek Biosciences, and it is filed as a passive investor report.
Historical context for CTKB
Across the 25 sessions after earlier CTKB headlines, the stock closed higher 13 times and lower 11 times, with a median move of 1.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CTKB | SPY |
|---|---|---|---|
| Oct 30, 2026 | Cytek Biosciences to Participate in Upcoming Investor Conferences | -2.7% | -1.8% |
| Oct 22, 2026 | Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026 | -1.3% | -1.2% |
| Sep 24, 2026 | Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool | +0.9% | -0.1% |
| Sep 9, 2026 | Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry | +2.4% | -0.5% |
| Sep 4, 2026 | Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS | +0.0% | -0.4% |
| Sep 2, 2026 | Cytek Biosciences to Participate in Upcoming Investor Conferences | +1.5% | +0.4% |
- Market cap
- 30-day
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Listed since
- 2021
Follow CTKB and get a push notification the moment its next story breaks.